...
Why us? Why us? please click dropdown
4.8/5 out of 3,500+ reviews
Regulated: CQC Registered | 1-5796078466
  • Verified Content: Approved by the Women’s Health Clinic Clinical Team.
  • Educational Use: This is not a substitute for professional medical advice, diagnosis, or treatment.
  • Clinical Assessment: Individual suitability is determined by a clinician; results may vary.
  • Non-NHS: Private healthcare provider only. Pricing varies by treatment and site. Availability varies by clinical location.
  • MEDICAL EMERGENCY:

    If you need urgent help, use NHS 111. For a life-threatening emergency, call 999.

Author Find more about the author
Dr Farzana Khan

Dr Farzana Khan

Verified

Dr Farzana Khan qualified as an MD from the University of Copenhagen in 2003. She has worked in dermatology and obstetrics & gynaecology across the North of England and completed her MRCGP (CCT, 2013) and the Diploma of the Faculty of Sexual & Reproductive Health (2013). Her clinical focus is vaginal health—including dryness/GSM, sexual function concerns, lichen sclerosus, and comfort or volume changes. She offers careful assessment, discusses medical and conservative options first, and considers selected regenerative or aesthetic treatments where appropriate. Dr Farzana also trains clinicians as a KOL/Trainer with Neauvia, Asclepion Laser, and RegenLab (since 2023). Ongoing CPD includes IMCAS, CCR, ACE and expert training in women’s intimate fillers, PRP, and polynucleotide injectables. Her approach is simple: clear explanations, realistic expectations, and shared decision-making.

MD MRCGP DFFP
Was this answer helpful?
Authored and medically reviewed by Dr Farzana Khan on 2 August 2026
Rate Dr Farzana's explanation



Condition-aware


May need deferral


Safety first

Women’s Health Clinic FAQ

Can an O-Shot injection trigger a temporary viral flare in patients with a history of genital herpes simplex virus (HSV-2)?

Conditions such as lichen sclerosus, HSV history and postmenopausal tissue change can alter whether an O-Shot is appropriate.

Direct answer

A genital injection may plausibly irritate tissue or stress a region with previous HSV, so HSV-2 history should be reviewed before an O-Shot. The page should discuss symptom awareness, deferral during outbreaks and clinician advice without promising prevention.

The answer should connect PRP biology with symptoms, medicines, anatomy, tissue health and evidence limits before suggesting whether treatment is suitable.


Educational only. Use this as general education before discussing your own symptoms with a clinician. Results vary. Not a cure.

Women's Health Clinic consultation for Can an O-Shot injection trigger a temporary viral flare in patients with a history of genital herpes simplex virus (HSV-2)?

O-Shot suitability review

At a glance

These points frame the question before considering treatment suitability.

At a glance

Clinical summary

Skin disease

Active vulval plaques or fissures should be assessed before injection.

HSV history

Previous genital herpes should be discussed before any genital procedure.

Menopause

Low-oestrogen tissue may be thinner, drier and more sensitive.

Deferral

Treatment may need delaying if there are active symptoms or red flags.

Important safety note

Seek medical advice promptly for heavy or persistent bleeding, fever, offensive discharge, ulcers, severe pelvic or vulval pain, urinary retention, active genital herpes symptoms, worsening swelling or symptoms that feel unusual after treatment.

PRP
Intimate health
Suitability
Evidence
Review




Detailed answer

Detailed answer

Condition-specific safety should come before any discussion of needle placement or likely response.

Clinical context

Active lichen sclerosus, HSV symptoms, infection, fissures, ulcers or unexplained bleeding can change the safety of genital injection.

Mechanism
Anatomy
Safety
Evidence

What matters first

Condition-specific safety should come before any discussion of needle placement or likely response.

Biological logic

Active lichen sclerosus, HSV symptoms, infection, fissures, ulcers or unexplained bleeding can change the safety of genital injection.

Evidence boundary

Postmenopausal mucosa may have reduced hydration and resilience, so sensitivity concerns need full GSM assessment.

Safety boundary

PRP should not be presented as a substitute for diagnosing or treating the underlying condition.

What this means in practice

A useful answer explains the mechanism without becoming a public protocol or a promise about sexual response.

Treatment details, medicine changes, anaesthetic plans, activity restrictions and treatment timing should be confirmed by the treating clinician.





Patient safety

Why this matters

O-Shot questions often sit at the intersection of sexual wellbeing, tissue sensitivity, pain, confidence and medical safety.

It avoids overpromising

PRP biology is plausible, but response in lubrication, orgasm, pain or sensitivity varies.

It protects sensitive tissue

Genital tissue can be affected by menopause, skin disease, infection, scarring, medicines and pelvic-floor pain.

It keeps anatomy clear

Clitoral, vaginal, vestibular, urethral and scar-related symptoms should not be blurred together.

It supports consent

Patients should understand uncertainty, discomfort, bleeding, bruising and aftercare before choosing treatment.

A careful treatment conversation

The right question is not only whether PRP could help, but whether it fits the patient's symptoms, tissue health and medical history.

That is why consultation, review and clear safety advice are central to responsible intimate PRP care.





Considerations

What to consider

Consider the main symptom, menopause status, medicines, platelet count, bleeding history, HSV history, vulval skin disease, infection symptoms, scarring, pelvic-floor pain and treatment goals.

Consultation priorities

Assessment reviews skin symptoms, outbreaks, dryness, pain, bleeding, discharge, urinary symptoms, menopause status and current treatment.

Symptoms
Medicines
Tissue
Follow-up

Assessment

Assessment reviews skin symptoms, outbreaks, dryness, pain, bleeding, discharge, urinary symptoms, menopause status and current treatment.

Safety review

Examination checks whether tissue is calm enough for a procedure or whether a medical condition needs stabilising first.

Treatment fit

If treatment is considered, consent should include uncertainty, flare risk, soreness, bleeding, infection and review pathways.

Review

Follow-up matters if pain, discharge, ulcers, outbreak symptoms or bleeding develop after treatment.

Practical expectations

Response can be partial, delayed or absent, and published intimate PRP protocols are not uniform.

Prices, exact products, injection details, treatment timing and aftercare should be confirmed with the clinic before booking.





Common concerns and myths

Common misconceptions

These myths can make the O-Shot sound either simpler or more predictable than the evidence supports.

Myth: PRP can simply be injected through active vulval disease

Reality: active plaques, fissures or inflammation may need stabilising first.

Myth: HSV history is irrelevant

Reality: previous outbreaks should be discussed before genital procedures.

Myth: postmenopausal sensitivity is only lubrication

Reality: GSM, skin disease, pelvic-floor pain and tissue fragility can overlap.

Evidence and context

Mechanism helps explain why PRP is considered, but it does not replace diagnosis, clinical evidence or suitability checks.

Different outcomes

Desire, arousal, lubrication, orgasm, pain and urinary symptoms are different outcomes and should be assessed separately.





Safety checklist

Safety checklist

Use these checks before assuming intimate PRP is suitable.

Is the symptom clear?

Clarify whether the concern is orgasm, arousal, lubrication, pain, sensitivity, urinary leakage or confidence.

Have medicines been reviewed?

Aspirin, antiplatelets, NSAIDs, supplements and clotting history can affect suitability and aftercare.

Are red flags absent?

Seek medical advice promptly for heavy or persistent bleeding, fever, offensive discharge, ulcers, severe pelvic or vulval pain, urinary retention, active genital herpes symptoms, worsening swelling or symptoms that feel unusual after treatment.

Is uncertainty documented?

Consent should explain limited evidence, variable response and possible discomfort, bruising or bleeding.

Reassuring signs

Proceeding is more reasonable when symptoms are clearly assessed, red flags are absent and expectations are realistic.

Clear goal
No red flags
Review plan

Reasons to pause

Seek medical advice promptly for heavy or persistent bleeding, fever, offensive discharge, ulcers, severe pelvic or vulval pain, urinary retention, active genital herpes symptoms, worsening swelling or symptoms that feel unusual after treatment.

Bleeding
Infection
Severe pain




When to escalate

When to seek medical help

Some symptoms around intimate PRP treatment need prompt assessment.

Use NHS 111 online

Bleeding

Heavy bleeding, persistent bleeding or bleeding after sex should be assessed by a clinician.

Infection symptoms

Fever, offensive discharge, worsening burning, ulcers or pelvic pain may need swabs, urine testing or review.

Herpes or skin flare

Blisters, ulcers, new vulval plaques or severe irritation should be assessed before further treatment.

Emergency symptoms

Call 999 in a life-threatening emergency, including collapse, chest pain, breathing difficulty or sudden neurological symptoms.

Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.

More clinical detail

Why active symptoms change the plan

Inflamed, fissured or infected genital tissue can be more painful and less predictable after injection. Deferral can be the safer clinical choice.

Why menopause context matters

Low-oestrogen tissue may be thinner, drier and more reactive. That does not rule treatment in or out, but it makes assessment essential.

Next step

Book an intimate health consultation

A consultation can clarify whether symptoms fit GSM, sexual-function concerns, pelvic-floor pain, urinary symptoms or another cause, and whether PRP is suitable.

View Research Sources (12 Sources)
• O-Shot official questions
• NHS lichen sclerosus
• NHS genital herpes
• PRP in vulvovaginal disorders systematic review
• NHS vaginal dryness
• Platelet-rich plasma administration to the lower anterior vaginal wall to improve female sexuality satisfaction - PMC
• Value of injection of plasma-rich platelets in the vaginal mucosa in cases with vulvovaginal atrophy: a prospective double-blinded randomised controlled study - PMC
• A case of herpes simplex virus reactivation after fractional ablative carbon dioxide laser to treat a burn scar - PubMed
• Clinical features of herpes simplex virus reactivation after microvascular decompression for trigeminal neuralgia: Experience of 200 patients and a literature review - PMC
• Guideline for the Management Herpes Simplex 1 and Cosmetic Interventions - PMC
• Herpes reactivation after the injection of hyaluronic acid dermal filler - PMC - NIH
• Herpes Simplex Infection in Treatment-Refractory Plasma Cell Vulvovaginitis - PMC

These 12 source names are selected from 212 curated sources. Additional reviewed material included professional society guidance, peer-reviewed clinical papers, evidence reviews; duplicate and low-relevance records were removed before display.

Educational only. This information is for education only and is not a substitute for professional medical advice, diagnosis or treatment. Results vary. Not a cure.

  • Clinical Assessment: Individual suitability is determined by a clinician; results may vary.
  • Non-NHS: Private healthcare provider only. Pricing varies by treatment and site. Availability varies by clinical location.